Osteoporosis: A paradox in ankylosing spondylitis

Current Osteoporosis Reports

Volumn 9, Issue 3, 2011, Pages 112-115

  Carter, Shea ^a   Lories, Rik J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Ankylosing spondylitis; Ankylosis; Arthritis; Bone growth; Bone loss; Osteoporosis

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN;

ANKYLOSING SPONDYLITIS; ARTICLE; BONE DENSITY; BONE REMODELING; DISEASE ASSOCIATION; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; SIGNAL TRANSDUCTION;

BONE DENSITY; BONE RESORPTION; HUMANS; INCIDENCE; OSTEOGENESIS; OSTEOPOROSIS; SIGNAL TRANSDUCTION; SPONDYLITIS, ANKYLOSING; WNT PROTEINS;

EID: 80054989186     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-011-0058-z     Document Type: Article

References (27)

1. Appel H et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum. 2006;54 (9):2845-51. (Pubitemid 44497763)
2. Schett G. Structural bone changes in spondyloarthritis: mechanisms, clinical impact and therapeutic considerations. Am J Med Sci. 2011;341(4):269-71.
3. El Maghraoui A. Osteoporosis and ankylosing spondylitis. Joint Bone Spine. 2004;71(4):291-5. (Pubitemid 39037316)
4. El Maghraoui A et al. Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol. 1999;26(10):2205-9. (Pubitemid 29487018)
5. Hanson CA, Shagrin JW, Duncan H. Vertebral osteoporosis in ankylosing spondylitis. Clin Orthop Relat Res. 1971;74:59-64.
6. Magrey M, Khan MA. Osteoporosis in ankylosing spondylitis. Curr Rheumatol Rep. 2010;12(5):332-6.
7. Maillefert JF et al. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int. 2001;12(7):605-9. (Pubitemid 32777439)
8. Karberg K et al. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol. 2005;32(7):1290-8. (Pubitemid 40995385)
9. Rubinstein HM. Osteoporosis in ankylosing spondylitis. Br J Rheumatol. 1991;30(2):160.
10. Will R et al. Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet. 1989;2(8678-8679):1483-5. (Pubitemid 20018143)
11. Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol. 2004;31(11):2236-41. (Pubitemid 39453245)
12. Ghozlani I et al. Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone. 2009;44(5):772-6.
13. Dasgupta B et al. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol. 1992;19 (1):22-5.
14. Roche NE et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36(9):1286-94. (Pubitemid 23303119)
15. Gratacos J et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol. 1994;33(10):927-31. (Pubitemid 24324807)
16. Melis L et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis. 2010;69(3):618-23.
17. Lubberts E et al. IL-17 promotes bone erosion in murine collageninduced arthritis through loss of the receptor activator of NFkappa B ligand/osteoprotegerin balance. J Immunol. 2003;170 (5):2655-62. (Pubitemid 36245658)
18. Jovanovic DV et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNFalpha, by human macrophages. J Immunol. 1998;160(7):3513-21. (Pubitemid 28164746)
19. KimHR, Lee SH, KimHY. Elevated serumlevels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology (Oxford). 2006;45(10):1197-200.
20. Vis M et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(11):1495-9. (Pubitemid 44629129)
21. Appel H et al. Immunohistochemical analysis of osteoblasts in zygapophyseal joints of patients with ankylosing spondylitis reveal repair mechanisms similar to osteoarthritis. J Rheumatol. 2010;37(4):823-8.
22. Lories RJ, Derese I, Luyten FP. Inhibition of osteoclasts does not prevent joint ankylosis in a mouse model of spondyloarthritis. Rheumatology (Oxford). 2008;47(5):605-8. (Pubitemid 351619197)
23. Obermayer-Pietsch BM et al. Vitamin D receptor initiation codon polymorphism, bone density and inflammatory activity of patients with ankylosing spondylitis. Osteoporos Int. 2003;14(12):995-1000. (Pubitemid 40824267)
24. De Keyser F et al. Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep. 2002;4(6):525-32.
25. Uderhardt S et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis. 2010;69(3):592-7.
26. Visvanathan S et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(2):175-82.
27. Toussirot E, Wendling D. Anti-inflammatory treatment with bisphosphonates in ankylosing spondylitis. Curr Opin Rheumatol. 2007;19(4):340-5. (Pubitemid 46884188)